Resumen

VENTIN, MD  y  LEON, C. Pamidronato en la enfermedad metastásica ósea. AVFT [online]. 2004, vol.23, n.1, pp.18-24. ISSN 0798-0264.

Background: The bony metastasis is a common complication of many cancer types. These predispose to the development of: pain, pathological fractures and hypercalcaemia, that reduce the quality of the patient’s life. Evidence of bony destruction increased in the illness metastasic exists. The biphosphonates like the Pamidronate, inhibit the activity osteoclastic and reduce the bony reasorption. Methods: Patient with bony metastasis determined by gammagrama, received Pamidronate endovenous (90 or 60 mg) or placebo, markers of bony reasorption and quality of life were evaluated before the treatment and through the study. Results: The level of calcium plasmatic and calcium urinary of 24 hours it didn’t vary in any group. The alkaline fosfatase descended not significantly in the treatment groups. The corrected DPD (cross-linked: Piridoline y Deoxipiridoline colagen), diminished not significantly in the groups. In the subscale of physical well-being clinical improvement was observed in the group of 90 mg (p 0,05). Conclusions: The monthly infusions of Pamidronate, improve the bony pain in patient with bony metastasis.

Palabras clave : Cancer; Metastasis; Pamidronate; Quality of life; Bony markers.